Retrospective Evaluation of Lung Pathology in Subjects With COVID-19

Non-interventional, Retrospective, Multicenter, Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial

Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of C21 on lung pathology in subjects previously hospitalised with COVID-19 and enrolled in the VP-C21-006 trial.

The study will collect available HRCT scans obtained prior to, during treatment with C21 or placebo and up to 24 weeks after trial completion.

HRCT scans will be assessed for ground glass opacity, reticulation, band opacity, fibrosis and consolidation by a central, blinded HRCT reader.

Inclusion Criteria:

• Written informed consent
• Previously included in the VP-C21-006 trial and received at least one dose of investigational medicinal product (IMP)
• Available record of at least one HRCT performed within 24 weeks after completion of VP-C21-006.

Exclusion Criteria:

• Participation in another interventional trial during the historical period covered by this study that could interfere with the study objectives or evaluation